MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these […]
Q3 revenue on record pace; SOLIS & COR to launch late Q4; Terravis pursuing validation and global partnerships West Seneca, New York, Sept. 23, 2025 — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a […]
In partnership with RxERP Financial, the program offers up to $350,000 per pharmacy and $1 million per wholesaler or manufacturer through trusted third-party financing partners, strengthening cash flow and supply chain resilience. TAMPA, FL / September […]
LIVERMORE, Calif., Sept. 22, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in fuel cells and hydrogen technologies, has delivered its next generation, state-of-the-art Honey Badger 50™ (“HB50”) portable power units to […]
LIVERMORE, Calif., Sept. 09, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN) an innovation-driven leader in the fuel cell and hydrogen technology sector, is proud to announce a major technological breakthrough in its strategic collaboration […]
NEW YORK, Sept. 10, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of […]
Company Achieves Consistent Growth With Four Straight Record Months; Gross Margin Expands 2,000+ Basis Points in Three Quarters; Production Hits Strongest Levels to Date West Seneca, New York, Sept. 09, 2025 — Worksport Ltd. (NASDAQ: […]
Company Reaffirms ≥$20 Million 2025 Revenue Target and Highlights Clear Path to Near-Term Operational Cash Flow Positivity West Seneca, New York, Aug. 13, 2025 — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S. based […]
NEW YORK, Sept. 2, 2025 — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor efficacy, a clean […]
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif., August 25, 2025—-Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), […]
LIVERMORE, Calif., Aug. 27, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in fuel cells and hydrogen technologies, is pleased to announce that it has engaged Fata Advisory, LLC to support the […]
TAMPA, FL / August 27, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) (“Wellgistics Health” or the “Company”), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the introduction of HubRx AI – a fully […]
LIVERMORE, Calif., Aug. 26, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation-driven leader in fuel cells and hydrogen technologies, is pursuing new initiatives in the space sector with the European Space Agency (ESA) […]
LIVERMORE, Calif., Aug. 21, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN), an innovation driven leader in the fuel cell and hydrogen technology space, has entered into an agreement with a U.S. based global leader […]
LIVERMORE, Calif., Aug. 18, 2025 — Advent Technologies Holdings, Inc. (NASDAQ: ADN) an innovation-driven leader in the fuel cell and hydrogen technology sector, is supplying its proprietary membrane electrode assembly technology to Stralis Aircraft, based […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
